Elocalcitol (CAS 199798-84-0): A Promising Vitamin D Analog for Therapeutic Research
Explore the multifaceted applications and research significance of Elocalcitol, a key compound in understanding VDR-mediated pathways.
Get a Quote & SampleProduct Core Value
Elocalcitol
Elocalcitol, a selective and orally active vitamin D receptor (VDR) agonist, is recognized for its potent anti-inflammatory properties and its ability to inhibit prostate cell growth. Its therapeutic potential is being explored for conditions such as benign prostatic hyperplasia (BPH) and endometriosis, where it targets critical cellular pathways.
- Elocalcitol for Benign Prostatic Hyperplasia Treatment: Research highlights elocalcitol's role in mitigating the static, dynamic, and inflammatory components of BPH.
- Vitamin D Receptor Agonist Elocalcitol: As a VDR agonist, it modulates various biological functions, making it a valuable tool for studying vitamin D signaling.
- Elocalcitol Anti-inflammatory Activity: Studies demonstrate its efficacy in reducing inflammation in various models, suggesting its use in inflammatory conditions.
- Elocalcitol Prostate Cancer Inhibition: The compound exhibits direct inhibitory effects on prostate cancer cell proliferation and invasion, offering avenues for cancer research.
Key Advantages
Targeted Therapeutic Action
Elocalcitol's selectivity as a VDR agonist allows for precise targeting of specific cellular pathways, offering potential for enhanced efficacy and reduced side effects in various disease treatments.
Versatile Research Tool
With its well-defined biological activities, Elocalcitol serves as a crucial research chemical for understanding vitamin D receptor mechanisms and exploring novel therapeutic strategies.
Promising Clinical Potential
The ongoing clinical investigations into Elocalcitol for conditions like BPH underscore its promise as a future therapeutic agent, supported by its favorable safety profile and demonstrated efficacy.
Key Applications
Benign Prostatic Hyperplasia (BPH)
Elocalcitol is being investigated for its therapeutic potential in treating BPH, addressing both static and dynamic components alongside inflammatory aspects.
Prostate Cancer Research
The compound's ability to inhibit prostate cancer cell growth makes it valuable for preclinical studies and drug development in oncology.
Endometriosis Management
Research suggests Elocalcitol may reduce endometriosis development by modulating inflammatory responses, offering a potential new avenue for treatment.
Inflammatory Conditions
Its demonstrated anti-inflammatory activity positions Elocalcitol as a compound of interest for research into various inflammatory diseases.